A changed manufacturing process needs evidence about the product before and after the change. Comparability asks whether observed differences could matter to product quality, safety or effectiveness.
ICH Q5E provides a framework for comparing a biological product before and after manufacturing changes. It emphasizes quality attributes and assessing whether additional nonclinical or clinical evidence is needed. It does not prescribe one universal testing strategy. The question concerns a specified process change and product; it should not be collapsed into a general claim that all batches, sites or related products are interchangeable. Q5E states that comparability does not necessarily mean the pre-change and post-change attributes are identical, but that they are highly similar and existing knowledge is predictive enough that differences have no adverse impact on safety or efficacy. For autologous CAR T cells FDA's 2024 guidance says historical lots may be inadequate and recommends side-by-side testing on the same starting material where possible, for example one leukapheresis split between the pre-change and post-change processes. FDA's July 2023 manufacturing-changes and comparability guidance for cellular and gene therapy products is still labelled draft, not for implementation, on FDA's page checked 9 November 2026.
Shares Chemistry, manufacturing and controls, Immune measurements and product evidence.
Shares Chemistry, manufacturing and controls, Immune measurements and product evidence.
Shares Vein-to-vein time and manufacturing slots, Cell-therapy release and potency testing.
Shares Cell-therapy release and potency testing, Immune measurements and product evidence.
Shares Vein-to-vein time and manufacturing slots, Cell-therapy release and potency testing.
Shares Cell-therapy release and potency testing, Biosimilar manufacturing and comparability.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/